Immitra Bio is developing a platform for scalable, one-time curative in-vivo gene editing therapies based on its novel mutation agnostic gene editing technology and digital target identification platform.
ImmitraBio has raised €2.6M across 1 funding round from 9 investors, most recently a round in Jul 2026. Based in Zurich, Switzerland; active in Healthtech. Data as of 22 Jul 2026.
Timing: too soon vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2026-07-21 | Other | €2.6M |
| Another VC,BackBone Ventures,ETH Foundation,Fongit,Kickfund,OCCIDENT+3 more |
| View deal → |
